ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$22.83

Market cap

$1.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

$1.06B

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
Arcutis Biotherapeutics's quick ratio has surged by 165% YoY and by 6% QoQ
ARQT's EPS has soared by 79% YoY and by 2.9% QoQ
Arcutis Biotherapeutics's equity has surged by 98% YoY but it has decreased by 8% QoQ
Arcutis Biotherapeutics's net income has shrunk by 66% YoY and by 4.6% QoQ
Arcutis Biotherapeutics's debt has increased by 39% YoY

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
50.24M
Market cap
$1.15B
Enterprise value
$1.06B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$150.3M
EBITDA
-$149.61M
Free cash flow
-$149.16M
Per share
EPS
-$3.35
Free cash flow per share
-$2.98
Book value per share
$8.26
Revenue per share
$0
TBVPS
$8.66
Balance sheet
Total assets
$432.89M
Total liabilities
$18.4M
Debt
$5.14M
Equity
$414.49M
Working capital
$414.21M
Liquidity
Debt to equity
0.01
Current ratio
32.03
Quick ratio
30.79
Net debt/EBITDA
0.57
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.9%
Return on equity
-45.9%
Return on invested capital
-70.4%
Return on capital employed
-35.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-1.64%
1 week
0.97%
1 month
5.26%
1 year
-14.69%
YTD
-18.84%
QTD
-16.34%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$150.53M
Net income
-$150.3M
Gross margin
N/A
Net margin
N/A
Arcutis Biotherapeutics's net income has shrunk by 66% YoY and by 4.6% QoQ
The company's operating income has shrunk by 64% YoY and by 4.5% QoQ

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
2.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARQT's EPS has soared by 79% YoY and by 2.9% QoQ
Arcutis Biotherapeutics's equity has surged by 98% YoY but it has decreased by 8% QoQ
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 4.4

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The company's return on invested capital has surged by 74% YoY and by 31% QoQ
The ROE has soared by 58% YoY and by 12% from the previous quarter
ARQT's return on assets is up by 26% year-on-year and by 10% since the previous quarter

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
The current ratio has soared by 171% YoY and by 5% from the previous quarter
Arcutis Biotherapeutics's quick ratio has surged by 165% YoY and by 6% QoQ
Arcutis Biotherapeutics's debt is 99% lower than its equity
Arcutis Biotherapeutics's equity has surged by 98% YoY but it has decreased by 8% QoQ
ARQT's debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.